Iron overload: An accelerator of deadly cell responses in stroke
A study has uncovered that iron orchestrates the activation of two damaging cell death pathways—ferroptosis and ...
pharmaphorum11h
Roche ends the 30-year US hiatus in new stroke drugs
In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...
Discovery of growth factor and receptor mechanism in brain could improve stroke care
Researchers at Karolinska Institutet have identified a new mechanism that may improve the treatment of ischemic stroke. The ...
News Medical on MSN6h
Research identifies iron as crucial driver of stroke-related cell death processes
Ischemic stroke continues to rank among the top causes of death and long-term disability globally. While advances in acute treatments like clot retrieval and thrombolysis have improved outcomes, the ...
Neurology Advisor11d
Developing Dementia After Stroke: What Is the Risk for Stroke Survivors?
Among stroke survivors, the risk of developing dementia after stroke is significantly high, highlighting the need for targeted prevention strategies.
pharmaphorum1d
Roche removes tenecteplase from phase 3 for stroke
Roche said it has removed its thrombolytic drug tenecteplase from phase 3 for for acute ischaemic stroke, along with several earlier-stage projects. The fibrin-specific plasminogen activator ...
Stroke Global Clinical Trials Market Review 2025: Regional, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End-Point Status
The "Stroke - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report provides an overview of Stroke Clinical trials scenario ...
appliedclinicaltrialsonline5d
PRESTIGE-AF Trial Shows DOACs Reduce Ischemic Stroke Risk in Intracerebral Hemorrhage Survivors, Heighten Bleeding Complications
Phase III PRESTIGE-AF trial shows that direct oral anticoagulants significantly lower the risk of ischemic stroke in ...
Business Wire27d
Prolong Pharmaceuticals to Present Preliminary Phase 1 Data from HEMERA-1 for PP-007 in Acute Ischemic Stroke (AIS) at the 2025 International Stroke Conference (ISC)
announced that it will present new clinical data from HEMERA-1 (Phase 1 clinical trial in AIS), at the International Stroke Conference (ISC) on February 5-7 th, 2025, in Los Angeles, California.